Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 7:53 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 16,122 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Active, not recruiting Not applicable Interventional

Psoriatic Arthritis D2P Screening

NCT04110522
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Direct to patient PsA Screening Questionnaire
Other
Lead sponsor
Jessica Walsh
Other
Eligibility
18 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 2 Interventional Results available

Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

NCT00971737
View directory record Official record
Conditions
Breast Cancer
Interventions
allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection

NCT02330445
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PRTX-100
Drug
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 1, 2026, 7:53 AM EST
Completed No phase listed Observational

Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)

NCT02208661
View directory record Official record
Conditions
Morquio A Syndrome, Mucopolysaccharidosis IV A
Interventions
Not listed
Lead sponsor
Nadia Ali, PhD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Nov 1, 2026, 7:53 AM EST
Terminated Phase 2 Interventional Results available

AMTEC IIT: Phase 2 Multiarm Study in TNBC

NCT03801369
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy, Capivasertib, Ceralasertib, Durvalumab, Olaparib, Quality-of-Life Assessment, Selumetinib
Procedure · Drug · Biological + 1 more
Lead sponsor
Gordon Mills, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 1, 2026, 7:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Redes III Patient Navigator Qol Study

NCT02275754
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
PN+LCNC, PN Only
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 1 Interventional

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

NCT01248494
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
BEZ235, BKM 120, Letrozole, BKM120
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04501666
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Nemolizumab 30 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Nov 1, 2026, 7:53 AM EST
Withdrawn Phase 1Phase 2 Interventional

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

NCT01340729
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
TPI 287
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 4 Interventional Results available

Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

NCT01143727
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Santyl, Tegaderm Hydrogel
Drug
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 2 Interventional Results available

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

NCT01097642
View directory record Official record
Conditions
Breast Cancer
Interventions
Cetuximab, Ixabepilone
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 1 Interventional

Effect of Different Skin Creams on TEWL

NCT03663673
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
EpiCeram, Aveeno Daily Moisturising Sheer Hydration Lotion®
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 40 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Nov 1, 2026, 7:53 AM EST
Not listed No phase listed Observational Accepts healthy volunteers

Epidemiology Study of Keloid

NCT01423383
View directory record Official record
Conditions
Keloid
Interventions
Not listed
Lead sponsor
Tirgan, Michael H., M.D.
Individual
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 3 Interventional Results available

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453
View directory record Official record
Conditions
Melanoma
Interventions
LGX818, MEK162, vemurafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 2 Interventional

Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells

NCT00948480
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Autologous tumor cells plus dendritic cells, GM-CSF
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Nov 1, 2026, 7:53 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer

NCT07664579
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Glioblastoma, Lung Carcinoma, Malignant Solid Neoplasm, Metastatic Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Nov 1, 2026, 7:53 AM EST
Not listed Phase 1 Interventional

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

NCT03878303
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AC0058TA, Placebo AC0058TA
Drug
Lead sponsor
ACEA Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 2 Interventional

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227
View directory record Official record
Conditions
Breast Cancer
Interventions
Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Nov 1, 2026, 7:53 AM EST
Recruiting Early Phase 1 Interventional

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

NCT06700070
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
Interventions
PBA-0111
Drug
Lead sponsor
Pure Biologics S.A.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Nov 1, 2026, 7:53 AM EST
Completed Phase 2 Interventional

SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment

NCT00005931
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
SU5416
Drug
Lead sponsor
SUGEN
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 7:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer

NCT04670445
View directory record Official record
Conditions
Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma, Unresectable Stage III Non-Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage, Stage IV Merkel Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma, Stage IV Basal Cell Carcinoma, Stage IV Breast Cancer, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Hepatocellular Cancer, Stage IV Renal Cell Carcinoma, Stage IV Bladder Cancer, Stage IV Head and Neck Squamous Cell Carcinoma, Stage IV Cervical Cancer, Stage IV Endometrial Cancer, Stage IV Mesothelioma, Immunotherapy, Immune Checkpoint Inhibitors
Interventions
Educational Video and QPL List, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 1, 2026, 7:53 AM EST
Completed Not applicable Interventional Results available

MediHoney for Radiation Dermatitis

NCT02234479
View directory record Official record
Conditions
Breast Cancer, Radiation Dermatitis
Interventions
Hydrophor (Group A), MediHoney (Group B)
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Nov 1, 2026, 7:53 AM EST
Recruiting Phase 2 Interventional

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

NCT07276880
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
Interventions
Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 1, 2026, 7:53 AM EST